VIVUS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-12-21: Form 8-K; Period of report 2011-12-21; Description 8.01 Other Events; Details 8.01.
- 2011-12-07: Form 8-K; Period of report 2011-12-07; Description 8.01 Other Events; Details 8.01.
- 2011-12-07: Form 8-K; Period of report 2011-12-07; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2011-11-10: Form 8-K; Period of report 2011-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-12-21 | 8-K | 2011-12-21 | 8.01 Other Events | 8.01 On December 21, 2011, VIVUS, Inc. issued a press release titled, “VIVUS Reports Topline Findings from FORTRESS.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-32087_18k.htm |
| 2011-12-07 | 8-K | 2011-12-07 | 8.01 Other Events | 8.01 On December 7, 2011, VIVUS, Inc. issued a press release titled, “SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-31234_18k.htm |
| 2011-12-07 | 8-K | 2011-12-07 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Representatives of VIVUS, Inc., or the Company, intend to deliver a presentation on December 7, 2011 to investors, potential investors, analysts and other individuals. 8.01 On December 7, 2011, Nancy JV Bohannon, MD, FACP, FACE delivered an oral presentation entitled, “Weight Loss and Diabetic Status in Obese (BMI >35) Diabetic Adults after 56 Weeks on Phentermine/Topiramate CR (PHEN/TPM CR)” at the International Diabetes Federation’s World Diabetes Congress, in Dubai, United Emirates. | a11-31161_18k.htm |
| 2011-11-10 | 8-K | 2011-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2011, VIVUS, Inc. conducted a conference call during which members of its senior management team discussed financial results for the third quarter ended September 30, 2011 and certain other information. | a11-29639_18k.htm |
| 2011-11-07 | 8-K | 2011-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2011, VIVUS, Inc. issued a press release regarding the results of its operations for the third quarter and nine months ended September 30, 2011 and certain other information. | a11-29331_18k.htm |
| 2011-11-03 | 8-K | 2011-11-03 | 8.01 Other Events | 8.01 · Qnexa® Phase 3 Data Published in Obesity Show 14.4% Average Weight Loss in Severely Obese Patients Completing One Year of Treatment. | a11-29141_18k.htm |
| 2011-10-17 | 8-K | 2011-10-17 | 7.01 Regulation FD Disclosure | 7.01 On October 17, 2011, VIVUS, Inc. issued a press release titled “VIVUS Resubmits Qnexa NDA to the FDA.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-28074_18k.htm |
| 2011-10-03 | 8-K | 2011-10-03 | 8.01 Other Events | 8.01 On October 3, 2011, VIVUS, Inc. issued a press release titled, “Two-Year Treatment with Qnexa has Benefits Beyond Weight Loss.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-27285_18k.htm |
| 2011-09-26 | 8-K | 2011-09-26 | 7.01 Regulation FD Disclosure | 7.01 On September 26, 2011, the Company announced that at the American Neurological Association, or ANA, meeting in San Diego, CA, a poster titled “Retrospective Analysis of Major Congenital Malformations and Oral Clefts Associated With In Utero Topiramate Exposure,” authored by Dr. Mark W. Green, Director of the Center for Headache and Pain Medicine and Professor of Neurology and Anesthesiology at the Mount Sinai School of Medicine, will be presented on Tuesday, September 27, 2011. | a11-26962_18k.htm |
| 2011-09-15 | 8-K | 2011-09-15 | 8.01 Other Events | 8.01 On September 15, 2011, VIVUS, Inc. issued a press release titled “VIVUS Provides Regulatory Update on QNEXA.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-26495_18k.htm |
| 2011-09-07 | 8-K | 2011-09-07 | 7.01 Regulation FD Disclosure | 7.01 On September 7, 2011, VIVUS, Inc., or the Company, gave a previously announced presentation at the Stifel Nicolaus 2011 Healthcare Conference being held in Boston, Massachusetts. | a11-26114_18k.htm |
| 2011-09-01 | 8-K | 2011-09-01 | 8.01 Other Events | 8.01 On September 1, 2011, VIVUS, Inc., or the Company, issued a press release titled, “VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-25434_18k.htm |
| 2011-08-31 | 8-K | 2011-08-31 | 8.01 Other Events | 8.01 On August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress (IEC) in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Columbia University Medical Center, presented the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure. | a11-25185_18k.htm |
| 2011-08-24 | 8-K | 2011-08-24 | 8.01 Other Events | 8.01 On August 24, 2011, VIVUS, Inc., or the Company, issued a press release announcing that the Company closed on the sale of a total of 6,889,098 shares of its common stock, at a price of $6.65 per share, pursuant to a previously-reported securities purchase agreement entered into on August 23, 2011 with certain investors in connection with a registered direct offering of the Company’s common stock, or the Offering. | a11-24901_18k.htm |
| 2011-08-23 | 8-K | 2011-08-23 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On August 23, 2011, VIVUS, Inc. issued a press release titled “VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-24846_18k.htm |
| 2011-08-05 | 8-K | 2011-08-05 | 8.01 Other Events | 8.01 On August 5, 2011, VIVUS, Inc. issued a press release titled “Obese Patients Treated with QNEXA Demonstrated Significant Improvement in Quality of Life.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-23829_18k.htm |
| 2011-08-04 | 8-K | 2011-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2011, VIVUS, Inc. conducted a conference call during which members of its senior management team discussed financial results for the second quarter and six months ended June 30, 2011 and certain other information. | a11-23739_18k.htm |
| 2011-08-01 | 8-K | 2011-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2011, VIVUS, Inc. issued a press release regarding the results of its operations for the second quarter and six months ended June 30, 2011 and certain other information. | a11-23314_18k.htm |
| 2011-07-29 | 8-K | 2011-07-29 | 8.01 Other Events | 8.01 On April 29, 2011, VIVUS, Inc. (the “Company”) filed its definitive proxy statement describing, among other things, the amendments to the Company’s 1994 Employee Stock Purchase Plan (the “Amended Plan”). | a11-23245_28k.htm |
| 2011-07-20 | 8-K | 2011-07-20 | 8.01 Other Events | 8.01 On July 20, 2011, VIVUS, Inc. issued a press release titled “Topiramate Exposure and Birth Defect Data to be Presented at the 29th International Epilepsy Congress.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-19681_18k.htm |
| 2011-06-30 | 8-K | 2011-06-30 | 8.01 Other Events | 8.01 On June 30, 2011, VIVUS, Inc. issued a press release titled “VIVUS Submits New Drug Application for Avanafil for the Treatment of Erectile Dysfunction.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-16052_18k.htm |
| 2011-06-28 | 8-K | 2011-06-27 | 7.01 Regulation FD Disclosure | 7.01 On June 27, 2011, VIVUS, Inc., or the Company, presented a poster presentation entitled, “Assessment of the Teratogenic Risk in Fetuses Exposed to Topiramate in Utero” beginning at 5:00 p.m. | a11-15509_18k.htm |
| 2011-06-27 | 8-K | 2011-06-26 | 7.01 Regulation FD Disclosure | 7.01 On June 26, 2011, VIVUS, Inc., or the Company, presented three poster presentations beginning at 12:00 noon PT at the American Diabetes Association 71st Scientific Sessions meeting held June 24 to June 28, 2011 at the San Diego Convention Center, San Diego, California. | a11-15509_28k.htm |
| 2011-06-20 | 8-K | 2011-06-17 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 17, 2011, VIVUS, Inc., or the Company, held its 2011 Annual Meeting of Stockholders, or the Annual Meeting. | a11-15207_18k.htm |
| 2011-06-17 | 8-K | 2011-06-17 | 7.01 Regulation FD Disclosure | 7.01 On June 17, 2011, Dr. John P. Mulhall, Director of the Male Sexual & Reproductive Medicine Program at the Memorial Sloan Kettering Cancer in New York, will present a poster presentation entitled: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral, Nerve-Sparing Radical Prostatectomy” beginning at 3:00 p.m. | a11-14957_18k.htm |
| 2011-05-27 | 8-K | 2011-05-27 | 7.01 Regulation FD Disclosure | 7.01 On May 27, 2011, Dr. Stephen Rössner will deliver an oral presentation entitled: “Cardiometabolic Risk Reduction is Directly Related to Magnitude of Weight Loss. | a11-12998_48k.htm |
| 2011-05-25 | 8-K | 2011-05-25 | 7.01 Regulation FD Disclosure | 7.01 On May 25, 2011, VIVUS, Inc. presented three poster presentations at the 2011 European Congress on Obesity (ECO) meeting being held May 25 to May 28, 2011, at the ICEC Lütfi Kirdar Convention & Exhibition Center in Istanbul, Turkey. | a11-12998_28k.htm |
| 2011-05-25 | 8-K | 2011-05-25 | 8.01 Other Events | 8.01 On May 25, 2011, VIVUS, Inc. issued a press release titled, “VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-12998_38k.htm |
| 2011-05-24 | 8-K | 2011-05-24 | 7.01 Regulation FD Disclosure | 7.01 On May 24, 2011, Dr. Suzanne Oparil will deliver an oral presentation entitled: “Evaluation of Cardiovascular Effects in Three Double-Blind, Placebo-Controlled Clinical Trials with Controlled-Release Phentermine/Topiramate (PHEN/TPM CR)” beginning at 8:15 a.m. | a11-12998_18k.htm |
| 2011-05-17 | 8-K | 2011-05-17 | 7.01 Regulation FD Disclosure | 7.01 On May 17, 2011, Dr. Laurence Belkoff, Chairman of the Department of Specialty Surgeries and the Division of Urology at the Philadelphia College of Osteopathic Medicine, will present a poster presentation entitled: “An Open-label, Long-term Evaluation of the Safety and Efficacy of Avanafil in Men With Erectile Dysfunction” beginning at 1:00 p.m. | a11-12358_18k.htm |
| 2011-05-06 | 8-K | 2011-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2011, VIVUS, Inc. conducted a conference call during which members of its senior management team discussed financial results for the first quarter ended March 31, 2011 and certain other information. | a11-11725_18k.htm |
| 2011-05-02 | 8-K | 2011-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2011, VIVUS, Inc. issued a press release regarding the results of its operations for the first quarter ended March 31, 2011 and certain other information. | a11-11304_18k.htm |
| 2011-04-11 | 8-K | 2011-04-11 | 8.01 Other Events | 8.01 On April 11, 2011, VIVUS, Inc. issued a press release titled “QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-10001_18k.htm |
| 2011-04-04 | 8-K | 2011-04-03 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On April 3, 2011, VIVUS, Inc, or the Company, presented a poster entitled “Weight Loss and Cardiovascular Risk Reduction Over 2 Years With Controlled-Release Phentermine-Topiramate” beginning at 1:30 p.m. 8.01 On April 4, 2011, VIVUS, Inc. issued a press release titled “Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits.” A copy of the press release is attached hereto as Exhibit 99.2. | a11-9034_18k.htm |
| 2011-03-04 | 8-K | 2011-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2011, VIVUS, Inc. conducted a conference call during which members of its senior management team discussed financial results for the fourth quarter and year ended December 31, 2010 and certain other information. | a11-7316_18k.htm |
| 2011-02-28 | 8-K | 2011-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2011, VIVUS, Inc. issued a press release regarding the results of its operations for the fourth quarter and year ended December 31, 2010 and certain other information. | a11-6874_18k.htm |
| 2011-01-26 | 8-K | 2011-01-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 21, 2011, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of VIVUS, Inc. (the “Company”) approved a new cash compensation arrangement for the Company’s non-employee directors, with the existing equity compensation arrangement remaining unchanged. | a11-4632_18k.htm |
| 2011-01-21 | 8-K | 2011-01-21 | 8.01 Other Events | 8.01 On January 21, 2011, VIVUS, Inc. issued a press release titled “VIVUS Provides Regulatory Update on QNEXA NDA.” A copy of the press release is attached hereto as Exhibit 99.1. | a11-4409_18k.htm |
| 2011-01-10 | 8-K | 2011-01-10 | 8.01 Other Events | 8.01 In connection with the Company’s attendance at the 29th Annual JP Morgan Healthcare Conference to be held in San Francisco, CA commencing on January 10, 2010, the Company will be distributing and presenting the slides attached as Exhibit 99.1 to this report. | a11-3050_18k.htm |